<DOC>
	<DOCNO>NCT02099396</DOCNO>
	<brief_summary>The purpose evaluate efficacy , safety effect survival lobaplatin Gemcitabine combination Docetaxel , provide kind completely new second-line chemotherapy program osteosarcoma patient aggressive-phase , provide accurate reliable evidence-based result clinical application lobaplatin osteosarcoma patient one third-generation platinum drug , consummate enrich clinical practice guidance osteosarcoma world .</brief_summary>
	<brief_title>A Clinical Trial Efficacy Safety Lobaplatin Gemcitabine Combination With Docetaxel Second-line Treatments Advanced Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . 840 year old , male female 2 . Osteosarcoma aggressivephase confirm histopathology . Local tumor isolate pulmonary focus must confirm pathological diagnosis , pathological examination require pulmonary multiple metastatic tumor ( Definition osteosarcoma aggressivephase : 1 . Primary tumor locally recurrent tumor impossible cure radically cure amputation patient refuse 2. osteosarcoma show distal metastasis , metastatic tumor unable radical cure operation local therapeutic method ( stereotaxic radiosurgery , argonhelium knife , ultrasonic focus knife ) 3. patient refuse could tolerate operation local treatment primary tumor metastatic tumor . ) But patient include : 1 . Pulmonary metastasis complicate three osseous metastasis focus time 2 . Local recurrent focus big 200mm3 3 . More three pulmonary metastasis focus big 3cm 4 . Diffusive pulmonary metastasis 5 . More 10 metastatic focus big 1 cm lung 6 . Intracranial metastasis 7 . Multiple metastasis pelvis 8 . Formation tumor embolus great vessel ( thigh vessel , iliac vessel , peritoneal cavity vessel , vessel armpit , infraclavicular vessel ) 9 . Coelom effusion 3 . Patients fails treatment firstline chemotherapeutics osteosarcoma ( HDMTX , ADM , DDP , IFO ) , ever use least three kind firstline drug . 4 . Patients show progression disease within six month neoadjuvant chemotherapy adjunctive chemotherapy osteosarcoma well firstline chemotherapy , permission subject legal representative obtain patient show progression disease six month . 5 . Measurable focus detect baseline accord RECIST 1.1 edition . 6 . ECOG physical efficiency score 01 , anticipate life span three month . 7 . Recovery previous treatment : accord NCICTC AE 4.0 edition , adverse reaction ( except baldness ) recover grade one even low . 8 . Peripheral hemogram blood biochemical indicator follow indicate proper organ function : Hemoglobin ( Hb ) ≥ 90g/L , Neutrophilic granulocyte ( ANC ) ≥1.5×109/L , Blood platelet count ( Plt ) ≥ 80×109/L , Serum creatinine ( Cr ) ≤ 1.5×upper normal limit ( ULN ) , blood urea nitrogen ( BUN ) ≤ 2.5×upper normal limit ( ULN ) ; Total bilirubin ( TB ) ≤ ULN ; Alkaline phosphatase ( ALP ) ≤ 2.5×ULN ; Aspartate aminotransferase ( AST ) glutamate pyruvate transaminase ( ALT ) ≤ 2.5×ULN ; albumen ( ALB ) ≥ 25 g/L。 9 . Pregnancy test ( urinary βHCG ) negative ( suitable woman reproductive life sexual activity ) . 10 . Informed consent ( signed legal representative ) sign testify understand purpose study operation require study , willing participate present study , subject 18 year old sign inform consent minor . 1 . Previous exposure lobaplatin / docetaxel , lobaplatin / gemcitabine , docetaxel / gemcitabine . 2 . Within three week last systemic cytotoxic drug medication , radiotherapy treatment test drug . 3 . Suffering malignant tumor past three year . Exceptions : skin basal cell carcinoma nonmetastatic squamous cell carcinoma , carcinoma situ uterine cervix , FIGO period 1 cervical cancer . 4 . Previously know metastasis central nervous system . 5 . Myocardial infarction within six month inclusion , grade II high cardiac failure define New York Cardiac Association , uncontrolled angina pectoris , uncontrolled severe ventricular arrhythmia , pericardial disease clinical significance , electrocardiogram indicate acute ischemia abnormality reactive conduct system . 6 . Uncontrolled complication , include confine : poorly control hypertension diabetes , persistent reactive infection , psychological disease social situation may affect compliance subject research . 7 . Previously know allergic reaction , hypersensitivity intolerance lobaplatin , docetaxel , gemcitabine adjuvant . 8 . Women pregnancy lactation . 9 . Any situation point researcher may impair subject lead incapability meet implement requirement research .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>PFS , efficacy safety , lobaplatin gemcitabine combination , second-line treatment advance osteosarcoma</keyword>
</DOC>